Serum gastrin concentrations and gastric acid secretion were measured during intravenous infusion of gastrin heptadecapeptide (G-17) (0, 7, 22.1, 70, 221, and 700 pmol/kg. h) in 15 duodenal ulcer patients and 15 healthy controls. Ulcer patients developed higher serum gastrin concentrations during G-17 infusion due to nearly twofold slower clearance of gastrin (8.8 vs. 15.7 ml/ kg-min; P < 0.01). Despite slower clearance of G-17, ulcer patients had plasma elimination half-times for G-17 similar to controls (6.0 vs. 6.1 min, respectively). Thus, calculated volume of distribution for G-17 was lower in ulcer patients than controls (78.5 vs. 140.7 ml/kg, P < 0.025). For any serum gastrin during gastrin-17 infusion, acid secretion (millimoles per hour) was higher in ulcer patients than in controls. However, when acid secretion was expressed as a percentage of peak acid output to G-17 (to correct for differences in parietal cell mass), curves relating acid secretion to serum gastrin were identical in ulcer patients and controls.
Introduction
Gastrin is a major endogenous stimulant ofgastric acid secretion, especially after a meal (1, 2) . Studies by Isenberg, Lam, and their associates have suggested that parietal cells ofpatients with duodenal ulcer (DU)' are more responsive to gastrin than parietal cells of normal subjects (2, 3) . This is controversial, however, since acid secretory responsiveness to exogenous gastrin was similar in DU patients and controls studied by Hirschowitz et al. (4, 5) . In the present study, we compared acid secretory responsiveness to human gastrin heptadecapeptide (G-17) in DU patients and controls. By infusing G-17 intravenously and by measuring acid secretion and serum gastrin concentrations simultaneously, we were able to relate acid secretion not only to the dose of exogenous G-17 infuised but also to circulating gastrin levels. By measuring serum gastrin concentration during G- 17 infusion, we could also compare metabolic clearance rates,
Methods
Studies were approved by the Human Research Review Committee of the Veterans Administration Medical Center, Dallas, TX. All patients and subjects gave written consent before participation in these experiments.
DU Patients and controls. 15 patients (12 male) with prior DU documented by upper gastrointestinal x-ray and/or endoscopy were studied. Their mean (±SE) age was 49±3 yr and their weights averaged 75.7±3.6 kg ( Table I ). All patients were asymptomatic at the time of these experiments. If patients were receiving antisecretory medications, these medications were discontinued 48 h before each study. The control group consisted of 15 healthy subjects (12 male) with an average age of 31±2 yr and an average weight of 71.5±3.5 kg (Table I ). Basal acid output and peak acid output to 6 jg/kg subcutaneous pentagastrin (PAO), measured in a preliminary study as previously described (6), averaged 7.4±1.8 and 46.4±3.0 mmol/h in the DU patients compared with 2.4±0.6 and 31.7±2.8 mmoVh in controls (P < 0.02 for basal acid output and P < 0.005 for PAO). Each DU patient and normal subject was then studied after an overnight fast, as described below.
G-1 7 infusion protocol. An intravenous catheter was placed in each arm and kept open by slow infusions of 0.15 M NaCL. A nasogastric tube was positioned in the dependent portion of the stomach under fluoroscopic guidance and residual gastric secretions were evacuated manually. After a 45-min basal period during which 0.15 M NaCI was infused intravenously, a solution of G-17 (synthetic human G-17-1; Research Plus, Bayonne, NJ) dissolved in 0.15 M NaCl and containing 1% human albumin was infused in doses of 7, 22.1, 70, 221, and 700 pmol/ kg. h. Each G-17 dose was infused over a 45-min period in a stepwise fashion (infusion pump 922; IMED Corp., San Diego, CA). Gastric secretions were collected by aspiration using a Stedman suction pump (American Cystoscope Makers, Inc., Stamford, CN), with suction applied for 48 out of every 60 s. Each sample of gastric juice was collected for 15 min. The volume was measured and the hydrogen ion concentration was determined by titration to pH 7.00 with 0.1 N NaOH. Acid output was calculated by multiplying volume times hydrogen ion concentration.
Blood specimens for serum gastrin assay were obtained from the catheter that had been placed in the arm opposite the G-17 infusion site. Specimens were drawn at the beginning of the experiment and also at 30, 37.5, and 45 min after beginning each 45-min infusion of NaCG or G-17. At the end of the 700 pmol/kg * h G-17 infusion, the infusion pump was turned off and additional blood specimens were obtained after 2, 5, 10, 15, and 30 min in order to compare plasma elimination rates for G-17 in the two groups of subjects (see below).
Serum gastrin radioimmunoassay. Because of the large number of sera (720 in all), two separate gastrin assays were necessary. Samples were divided so that an equal number from the DU and control groups could be included in each assay. Sera were coded and shipped from Dallas, TX to Los Angeles, CA on dry ice. Serum gastrin concentration was measured using antibody 161 1 as previously described (7 Fig. 1 A, basal serum gastrin concentrations were identical in DU patients and controls. On the other hand, steady-state serum gastrin concentrations during G-17 infusion in DU patients were approximately twice those of controls, and differences reached statistical significance with G-17 doses of 221 and 700 pmol/kg -h (P < 0.01). From serum gastrin data during and after discontinuation ofG-17 infusion ( Fig. 1 A) and subject from the slopes of their own regression equations, clearance averaged 8.6±1.1 ml/kg min in DU patients and 14.8±1.9 ml/kg min in controls (P < 0.01).
Clearance was also calculated using the plateau principle from the following equation: clearance = G-17 infusion rate/ AG, where AG is the steady-state basal-subtracted serum gastrin concentration (8, 9) . We used serum gastrin concentrations during infusion of 700 pmol/kg. h G-17 (Fig. I A) . As shown in Table I , clearance was 8.8±1.1 and 15.7±2.1 ml/kg-min for DU patients and controls, respectively (P < 0.01). Thus, regardless ofthe method used to calculate clearance (slope or plateau principle), DU patients cleared G-17 approximately halfas rapidly as controls.
G-1 7 plasma elimination half-'ife. After discontinuing the 700 pmol/kg h G-17 infusion, basal-subtraced serum gastrin concentrations were used to determine the plasma elimination rate for gastrin (Ke) (Fig. 1 A) . Initial pharmacokinetic parameter estimates were determined using the CSTRIP computer program (10). We then used an iterative nonlinear least-squares fitting program, NONLIN, to fit each set of data and obtain final estimates of the parameters (1 1 Acid secretion. For each G-17 dose (7, 22.1, 70, 221, and 700 pmol/kg. h), mean acid output was significantly higher in DU patients than controls (Fig. 1 B) . Maximal acid output was achieved with the 70 pmol/kg. h dose in both groups. When mean (±SE) steady-state serum gastrin concentrations for each G-17 dose were plotted against corresponding acid outputs, mean acid output was higher in DU patients than controls for any given serum gastrin concentration (Fig. 3 A) . To correct for differences in PAO and parietal cell mass between DU patients and controls, acid output was also expressed as a percent ofPAO (Fig. 3 B) . Curves relating serum gastrin concentration to acid output expressed as a percent of PAO were identical, suggesting equal sensitivity to circulating gastrin in the two groups. Sensitivity was further examined by calculating the 50% effective dose (ED50) for G-17 and the 50% effective concentration (EC,0) for circulating gastrin (see below). ED50. A linear relationship existed between log G-17 dose and acid output expressed as a percent of PAO (using G-17 doses of7-70 pmol/kg -h). For example, correlation coefficients in DU patients averaged 0.95±0.02 (range, 0.69-1.00) and correlation coefficients in controls averaged 0.96±0.01 (range, 0.87-1.00). The 30 individual linear regression equations were solved for the log G-17 dose corresponding to an acid output of 50% of PAO, and then this log dose was converted to the ED50 in picomoles per kilograms times hours. As shown in Fig. 4 A, mean ED50 was lower in DU patients than in controls (12.4±2.4 vs. 20.6±5.5 pmol/kg* h), but this difference was not significant.
EC50. There was a linear relationship between log serum gastrin concentration (using G-17 doses of 0-70 pmol/kg * h) and acid output expressed as a percentage ofPAO (r = 0.97+0.01 in DU; range, 0.90-1.00; r = 0.96±0.02 in controls; range, 0.75-1.00). Individual linear regression equations were solved for the log serum gastrin concentration corresponding to an acid output of 50% of PAO, and then the log concentration was converted to serum gastrin concentration in picograms per milliliter (EC50). As shown in Fig. 4 , mean EC50 was not significantly different in DU patients and controls (74±12 vs. 63±14 pg/ml, respectively). Thus, as defined by EC50, DU patients and controls were equally responsive to circulating gastrin.
Discussion
A major purpose of our study was to compare parietal cell responsiveness to G-17 in DU patients and controls. To compare responsiveness to a stimulant such as gastrin, differences in parietal cell mass must be considered. From the classic studies of Card and Marks, parietal cell mass is thought to correlate closely with PAO (12) . In our study, mean PAO to G-17 (and to pentagastrin) was significantly higher in DU patients than controls, reflecting an increased parietal cell mass (13) . To correct for differences in parietal cell mass, acid secretion in response to the stimulant is conventionally expressed as a percentage of PAO. Then, ED50 (i.e., the dose of stimulant required to produce 50% Fig. 4 B) . Therefore, our results indicate that parietal cells of DU patients and normal controls have identical responsiveness (sensitivity) to circulating human G-17, a conclusion recently reached by Hirschowitz et al. (5) .
An unexpected finding in this study was that DU patients had a slower clearance ofexogenous G-17 and a smaller volume of distribution for G-17 than did controls. In contrast to our results, Eysselein et al. reported similar metabolic clearance rates and volumes of distribution for G-17 in five DU patients and six controls with mean ages similar to those in our study (7) . It is unclear why our DU patients had a smaller apparent volume of distribution than our controls, yet the observed differences in clearance can only be explained by differences in distribution, since elimination rate constants were similar. G-17 elimination half-lives of -6 min in DU patients and controls have been previously reported (7, 16) .
We considered the possibility that differences in gastrin pharmacokinetics in our DU patients and controls could be related to the DU patients' older mean age. However, we were unable to find a significant correlation between age and metabolic clearance (r = -0.30) or volume of distribution (r = -0.20). Furthermore, clearance and volume of distribution of G-17 in our five youngest DU patients (mean age, 36 yr) averaged 9 (Table I) . Thus, age is an unlikely explanation for the almost twofold differences in clearance and volume of distribution we observed between DU patients and healthy subjects. Whether the alteration in clearance of G-17 in DU patients is of clinical importance remains unknown.
